Spyre Therapeutics Inc (SYRE)

$80.79 +0.02 (0.02%)
Market Cap 7.02B
Revenue (ttm) 0.00
Net Income (ttm) -155.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 958,700
Avg Vol 1,229,904
Day's Range N/A - N/A
Shares Out 86.84M
Stochastic %K 77%
Beta 3.05
Analysts Strong Sell
Price Target $96.07

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necros...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 5940
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
BreakoutsHappen
BreakoutsHappen Jun. 15 at 9:05 AM
$VECO Breakouts; $SYRE $STM $ALAB $DELL
0 · Reply
oaksapollo
oaksapollo Jun. 13 at 1:56 AM
$SYRE $7B cap, absolute insanity. Years from commercialization, loaded with clinical execution risk, fierce competition, and sure to dilute significantly between now and any potential approval. No idea why anyone wants to own this. If options ever become more liquid I will be making bearish bets on a regular basis.
1 · Reply
SoxFan666
SoxFan666 Jun. 9 at 3:18 PM
$SYRE been real busy and just checked my Schwab account: i got a divy for 8k on 5/15. is this real?
0 · Reply
mnzg
mnzg Jun. 8 at 3:16 PM
$SYRE i had 25268 agle shares back in 22-23 and i have not been following it since then but i just checked my account and it says i have dividend (not credited into my account yet) but we should also be getting 1 SYRE share for 25 AGLE shares right ? Can someone who knows about this help to understand please ? Many thanks in advanve
2 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 4 at 3:07 PM
$SYRE Never left
1 · Reply
StockConsultant
StockConsultant Jun. 4 at 1:48 PM
$SYRE Spyre Therapeutics stock, watch for a bull flag breakout at https://stockconsultant.com/?SYRE Breakout trade WATCH for possible breakout above 78.45 Target: 91.89, 19.2% Stop: 71.78 Loss: 6.9% P/L ratio: 2.8 : 1 - Good BULLISH [Timing] Strong bullish 3 day candlestick pattern with Extreme 3 day accumulation. [Timing] Extreme bullish 1 day moneyflow [Timing] breakout watch above 78.45, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
0 · Reply
Quantumup
Quantumup Jun. 4 at 11:35 AM
Deutsche Bank⬆️ $SYRE's PT to $115 (was $102) and reiterated Buy. $JNJ ABBV TAK APGE $ABVX Here's what Deutsche Bank said in its note: https://x.com/Quantumup1/status/2062497861581844711?s=20
0 · Reply
anachartanalyst
anachartanalyst Jun. 4 at 10:02 AM
$SYRE https://anachart.com/wp-content/uploads/2026/06/1780567272_soc-img.jpg
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 8:03 AM
$SYRE Share Price: $69.22 Contract Selected: Nov 20, 2026 $70 Calls Buy Zone: $14.54 – $17.96 Target Zone: $26.22 – $32.04 Potential Upside: 70% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ImadogImaMut
ImadogImaMut Jun. 1 at 5:07 PM
$SYRE I’ve had this on my list Well today my friends today 🏎️☮️
0 · Reply
Latest News on SYRE
Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 3 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Spyre Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 10:00 AM EDT - 6 days ago

Spyre Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Spyre Therapeutics Announces Grants of Inducement Awards

Jun 5, 2026, 4:01 PM EDT - 9 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank

2026-06-04T08:35:09.000Z - 11 days ago

Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank

ABVX

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 11 days ago

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072

2026-06-03T13:10:31.000Z - 11 days ago

Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Jun 3, 2026, 8:00 AM EDT - 11 days ago

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

Spyre Therapeutics Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 12 days ago

Spyre Therapeutics Slides: Corporate presentation

Spyre Therapeutics management to meet with BTIG

2026-05-27T19:00:13.000Z - 18 days ago

Spyre Therapeutics management to meet with BTIG

Spyre Therapeutics Transcript: AGM 2026

May 27, 2026, 12:00 PM EDT - 18 days ago

Spyre Therapeutics Transcript: AGM 2026

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 26, 2026, 4:10 PM EDT - 19 days ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank

2026-05-12T14:50:09.000Z - 4 weeks ago

Spyre Therapeutics price target raised to $102 from $86 at Deutsche Bank

Spyre Therapeutics price target raised to $97 from $64 at Citi

2026-05-07T08:43:33.000Z - 5 weeks ago

Spyre Therapeutics price target raised to $97 from $64 at Citi

Spyre Therapeutics price target raised to $107 from $92 at Stifel

2026-05-07T07:55:33.000Z - 5 weeks ago

Spyre Therapeutics price target raised to $107 from $92 at Stifel

Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)

2026-05-05T12:27:39.000Z - 5 weeks ago

Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026, 8:00 AM EDT - 5 weeks ago

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Spyre Therapeutics Quarterly report: Q1 2026

Spyre Therapeutics Earnings release: Q1 2026

May 5, 2026, 7:00 AM EDT - 5 weeks ago

Spyre Therapeutics Earnings release: Q1 2026

Spyre Therapeutics price target raised to $95 from $64 at JonesResearch

2026-04-17T09:05:40.000Z - 2 months ago

Spyre Therapeutics price target raised to $95 from $64 at JonesResearch

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Apr 16, 2026, 4:15 PM EDT - 2 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Spyre Therapeutics 6.5M share Secondary priced at $62.00

2026-04-15T09:50:13.000Z - 2 months ago

Spyre Therapeutics 6.5M share Secondary priced at $62.00

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Apr 14, 2026, 10:38 PM EDT - 2 months ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Spyre Therapeutics price target raised to $90 from $65 at Baird

2026-04-14T11:44:26.000Z - 2 months ago

Spyre Therapeutics price target raised to $90 from $65 at Baird

Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo

2026-04-14T10:30:34.000Z - 2 months ago

Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo

Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank

2026-04-14T08:40:36.000Z - 2 months ago

Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank

Spyre Therapeutics announces $300M offering of common stock

2026-04-13T20:50:45.000Z - 2 months ago

Spyre Therapeutics announces $300M offering of common stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Apr 13, 2026, 4:46 PM EDT - 2 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Spyre Therapeutics initiated with a Strong Buy at Raymond James

2026-04-13T20:12:35.000Z - 2 months ago

Spyre Therapeutics initiated with a Strong Buy at Raymond James

Spyre Therapeutics price target raised to $80 from $65 at Wedbush

2026-04-13T18:55:50.000Z - 2 months ago

Spyre Therapeutics price target raised to $80 from $65 at Wedbush

TAK

Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen

2026-04-13T18:55:10.000Z - 2 months ago

Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen

Spyre Therapeutics price target raised to $106 from $49 at Leerink

2026-04-13T18:45:43.000Z - 2 months ago

Spyre Therapeutics price target raised to $106 from $49 at Leerink

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

2026-04-13T18:36:05.000Z - 2 months ago

Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data

Spyre Therapeutics Transcript: Study result

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Spyre Therapeutics Transcript: Study result

Spyre Therapeutics Press release: Study result

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Spyre Therapeutics Press release: Study result

Spyre Therapeutics Slides: Study result

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Spyre Therapeutics Slides: Study result

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Apr 13, 2026, 7:00 AM EDT - 2 months ago

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Apr 10, 2026, 4:05 PM EDT - 2 months ago

Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

Spyre Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Spyre Therapeutics Proxy statement: Proxy filing

Spyre Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Spyre Therapeutics Proxy statement: Proxy filing

Spyre Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:40 AM EDT - 3 months ago

Spyre Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Spyre Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 3:10 PM EST - 3 months ago

Spyre Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 3 months ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 19, 2026, 4:02 PM EST - 4 months ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Earnings release: Q4 2025

Feb 19, 2026, 7:00 AM EST - 4 months ago

Spyre Therapeutics Earnings release: Q4 2025

Spyre Therapeutics Annual report: Q4 2025

Feb 19, 2026, 7:00 AM EST - 4 months ago

Spyre Therapeutics Annual report: Q4 2025

Spyre Therapeutics Registration statement: Registration Filing

Feb 19, 2026, 7:00 AM EST - 4 months ago

Spyre Therapeutics Registration statement: Registration Filing

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Jan 12, 2026, 8:00 AM EST - 5 months ago

Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Spyre Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:55 AM EST - 6 months ago

Spyre Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 3:00 AM EST - 7 months ago

Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Spyre Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:40 AM EST - 7 months ago

Spyre Therapeutics Transcript: Stifel 2025 Healthcare Conference

Spyre Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 10:00 AM EST - 7 months ago

Spyre Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Spyre Therapeutics Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 7 months ago

Spyre Therapeutics Slides: Corporate Presentation

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:05 PM EST - 7 months ago

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Nov 4, 2025, 4:01 PM EST - 7 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

Spyre Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 7:00 AM EST - 7 months ago

Spyre Therapeutics Earnings release: Q3 2025

Spyre Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 7:00 AM EST - 7 months ago

Spyre Therapeutics Quarterly report: Q3 2025

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Oct 24, 2025, 8:00 AM EDT - 8 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Oct 15, 2025, 4:15 PM EDT - 8 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Oct 13, 2025, 9:07 PM EDT - 8 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Oct 13, 2025, 4:01 PM EDT - 8 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Oct 5, 2025, 9:00 AM EDT - 9 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

Spyre Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 15, 2025, 10:00 AM EDT - 9 months ago

Spyre Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 8, 2025, 4:05 PM EDT - 9 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:02 PM EDT - 11 months ago

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Spyre Therapeutics Earnings release: Q2 2025

Spyre Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 11 months ago

Spyre Therapeutics Quarterly report: Q2 2025

Spyre Therapeutics Transcript: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Transcript: Status Update

Spyre Therapeutics Press release: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Press release: Status Update

Spyre Therapeutics Slides: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Slides: Status Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Jun 17, 2025, 7:30 AM EDT - 1 year ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics Slides: Corporate Presentation

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Spyre Therapeutics Slides: Corporate Presentation

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Jun 16, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 9:20 AM EDT - 1 year ago

Spyre Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Spyre Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Spyre Therapeutics Earnings release: Q1 2025

Spyre Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Spyre Therapeutics Quarterly report: Q1 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 5, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Proxy statement: Proxy Filing

Spyre Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Proxy statement: Proxy Filing

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Spyre Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Spyre Therapeutics Slides: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Spyre Therapeutics Slides: TD Cowen 45th Annual Healthcare Conference

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 9:30 AM EST - 1 year ago

Spyre Therapeutics Earnings release: Q4 2024

Spyre Therapeutics Annual report: Q4 2024

Feb 27, 2025, 9:30 AM EST - 1 year ago

Spyre Therapeutics Annual report: Q4 2024

Spyre Therapeutics Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Spyre Therapeutics Registration statement: Registration Filing

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Feb 19, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Jan 13, 2025, 8:00 AM EST - 1 year ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Slides: Corporate Presentation

Jan 13, 2025, 7:00 AM EST - 1 year ago

Spyre Therapeutics Slides: Corporate Presentation

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 2, 2024, 8:00 AM EST - 1 year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:11 PM EST - 1 year ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

BreakoutsHappen
BreakoutsHappen Jun. 15 at 9:05 AM
$VECO Breakouts; $SYRE $STM $ALAB $DELL
0 · Reply
oaksapollo
oaksapollo Jun. 13 at 1:56 AM
$SYRE $7B cap, absolute insanity. Years from commercialization, loaded with clinical execution risk, fierce competition, and sure to dilute significantly between now and any potential approval. No idea why anyone wants to own this. If options ever become more liquid I will be making bearish bets on a regular basis.
1 · Reply
SoxFan666
SoxFan666 Jun. 9 at 3:18 PM
$SYRE been real busy and just checked my Schwab account: i got a divy for 8k on 5/15. is this real?
0 · Reply
mnzg
mnzg Jun. 8 at 3:16 PM
$SYRE i had 25268 agle shares back in 22-23 and i have not been following it since then but i just checked my account and it says i have dividend (not credited into my account yet) but we should also be getting 1 SYRE share for 25 AGLE shares right ? Can someone who knows about this help to understand please ? Many thanks in advanve
2 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 4 at 3:07 PM
$SYRE Never left
1 · Reply
StockConsultant
StockConsultant Jun. 4 at 1:48 PM
$SYRE Spyre Therapeutics stock, watch for a bull flag breakout at https://stockconsultant.com/?SYRE Breakout trade WATCH for possible breakout above 78.45 Target: 91.89, 19.2% Stop: 71.78 Loss: 6.9% P/L ratio: 2.8 : 1 - Good BULLISH [Timing] Strong bullish 3 day candlestick pattern with Extreme 3 day accumulation. [Timing] Extreme bullish 1 day moneyflow [Timing] breakout watch above 78.45, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
0 · Reply
Quantumup
Quantumup Jun. 4 at 11:35 AM
Deutsche Bank⬆️ $SYRE's PT to $115 (was $102) and reiterated Buy. $JNJ ABBV TAK APGE $ABVX Here's what Deutsche Bank said in its note: https://x.com/Quantumup1/status/2062497861581844711?s=20
0 · Reply
anachartanalyst
anachartanalyst Jun. 4 at 10:02 AM
$SYRE https://anachart.com/wp-content/uploads/2026/06/1780567272_soc-img.jpg
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 3 at 8:03 AM
$SYRE Share Price: $69.22 Contract Selected: Nov 20, 2026 $70 Calls Buy Zone: $14.54 – $17.96 Target Zone: $26.22 – $32.04 Potential Upside: 70% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ImadogImaMut
ImadogImaMut Jun. 1 at 5:07 PM
$SYRE I’ve had this on my list Well today my friends today 🏎️☮️
0 · Reply
CH_Expat
CH_Expat May. 22 at 6:19 PM
$SYRE @CDMO One in the guts for the long weekend.
2 · Reply
FennickTradings
FennickTradings May. 19 at 1:55 PM
$SYRE got the payout🔥
1 · Reply
MissFred
MissFred May. 18 at 4:03 PM
$SYRE Remember Aeglea Theraputics ? I$ do
0 · Reply
MissFred
MissFred May. 18 at 3:59 PM
$SYRE
0 · Reply
outlawinvestor1
outlawinvestor1 May. 16 at 10:04 AM
updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO
1 · Reply
oaksapollo
oaksapollo May. 12 at 3:46 AM
$SYRE this is the most absurd valuation in biotech right now. Anyone can use YTE and do what they’re doing.
1 · Reply
chking09
chking09 May. 11 at 5:28 PM
$SYRE breakout?
0 · Reply
Quantumup
Quantumup May. 6 at 11:12 AM
Stifel y'day⬆️ $SYRE's PT to $107 (was $92), reit'd at Buy/said: Following best-in-class UC PoC data for SPY001 (α4β7), SYRE is well-positioned heading into additional PoC cohorts for SPY002 (TL1A) and SPY003 (IL-23p19) in mid-year/3Q26. $JNJ TAK APGE ABVX $ABBV Here's what else Stifel had to say: https://x.com/Quantumup1/status/2051982840607215753?s=20
0 · Reply
d_risk
d_risk May. 5 at 2:55 PM
$SYRE - Spyre Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +208.0% above peer average (36,855 vs 11,964 across 652 peers). SYRE’s 10-Q sharpens its downside: survival now explicitly hinges on new capital despite a large cash balance; it doubles down on going-concern, perpetual-loss, and no-revenue risks; concentrates dependence on four core programs and complex drug/device, biologics and CMC hurdles; and materially expands regulatory, IP, manufacturing, AI, talent, pricing, geopolitical and control‑weakness risks that could dilute shareholders, delay approvals and cripple commercialization. 🟢 Added 🟠 Removed https://d-risk.ai/SYRE/10-Q/2026-05-05
0 · Reply
Merlintrader
Merlintrader Apr. 30 at 11:10 PM
$SYRE Spyre Therapeutics 2026 (Nasdaq: $SYRE): When Great Clinical Data Matter More Than Promises https://www.merlintrader.com/spyre-therapeutics-may2026-deepdive/
0 · Reply
draketdot
draketdot Apr. 30 at 10:19 PM
$SYRE 33% increase incoming?
0 · Reply